STTK MEXC RealStocks
Own real STTK shares through MEXC's regulated brokerage partner.
Suitable for long-term holding.
- Own the actual shares
- Receive dividends and voting rights
- Buy fractional shares starting at $1
Last updated: 2026-11-19 08:32:40. Prices reflect the latest closing data and will resume updating on the next trading day. Stock price data is sourced from Massive.
Shattuck Labs, Inc. (STTK) operates in the PHARMACEUTICAL PREPARATIONS sector and is listed on NASDAQ. The stock is currently priced at $4.47, with a market capitalization of $467.46M and a P/E ratio of --. Over the past 52 weeks, its price has ranged from $1.88 to $8.33. This page covers its latest market performance, valuation, price trends and company information.
$467.46M | |
$4.58 | |
$4.89 | |
$4.35 | |
$4.59 | |
1.83M | |
1.19M | |
-- | |
$8.33 | |
$1.88 | |
-- | |
2026-09-30 |
Shattuck Labs, Inc. (STTK) last closed at $4.47 as of 2026-11-19 00:31:00, down 2.61% ($0.12) from the previous close of $4.59.
During the latest regular trading session, STTK traded between $4.35 and $4.89, with a volume of 1.83M shares. The closing price was near the lower end and near the middle of its 52-week range.
Over the past seven days, Shattuck Labs, Inc. (STTK) moved from $4.85 to $4.47, representing a decline of 7.77% ($0.38).
The stock traded between $4.34 and $5.10 during the period. The latest price is near the lower end of the 7-day range, indicating strong downward.
The average daily volume was 1.14 million shares, up versus the previous seven-day period, indicating higher trading activity.
Position in Range: 40.2%
STTK is currently trading at $4.47, placing it 40.2% of the way from its 52-week low of $1.88 to its 52-week high of $8.33. This percentage reflects the stock's relative position within its 52-week trading range, not its valuation or future performance.
Shattuck Labs Inc is a biotechnology company specializing in the development of potential treatments for inflammatory and immune-mediated diseases. It is developing a potentially first-in-class antibody for the treatment of inflammatory bowel disease (IBD) and other inflammatory and immune-mediated diseases. The company's expertise in protein engineering and the development of novel tumor necrosis factor (TNF) receptor therapeutics comes together in its main program, SL-325, which has the potential to be a first-in-class death receptor 3 (DR3) antagonist antibody. In addition, the company is developing SL-425, a half-life extended version of SL-325, and multiple other preclinical DR3-based bispecific antibodies, for the treatment of patients with IBD.
| Industry | PHARMACEUTICAL PREPARATIONS |
| Employees | 40 |
| Exchange | NASDAQ |
| Company Website |
Eligible investors can buy real shares of Shattuck Labs, Inc. (STTK) through MEXC RealStocks. Follow these three steps to open a RealStocks account, transfer USDT, and place a US stock order.
Stock prices and market data on this page, including price changes and market status, are provided by Massive and other third-party news and data platforms. Market data may be delayed and may differ from prices on other platforms or the prices at which trades are executed on MEXC. MEXC does not guarantee the accuracy, completeness, or timeliness of third-party data. MEXC offers trading products related to STTK, including Stocks, Tokenized Stocks, and Stock Futures.
The stock price information displayed on this page is provided for reference purposes only and may be delayed or differ from real-time market data. Prices, charts, and related metrics do not constitute investment advice and should not be relied upon for trading or investment decisions. MEXC is not responsible for any losses incurred based on the stock price information provided on this page. Please refer to official market sources or consult licensed financial professionals before making any investment decisions.
Estimate the value between STTK shares and USD.
STTK Shares to USD
1.00 STTK shares = 4.473 USD
Calculations are estimates based on the latest available price and are for reference only.